

## APPOINTMENT OF NON-EXECUTIVE CHAIR

**Perth, Australia; 30 NOVEMBER 2023** - Argenica Therapeutics Limited (ASX: AGN) (“Argenica” or the “Company”), is pleased to advise of the appointment of Ms Dianne Angus as Non-Executive Chair, effective 1 December 2023.

Ms Angus brings extensive executive managerial and company director experience in the biotechnology, biopharmaceutical, agritech and healthcare industries. She has long been involved in path to market asset development and commercialisation in these industries, notably including the clinical validation of drug therapeutics to create asset valuation uplift. Ms Angus has held Director roles in a number of ASX and NASDAQ-listed companies and as is currently a Non-Executive of Neuren Pharmaceuticals (ASX: NEU), Cyclopharm (ASX: CYC) and Imagion Biosystems (ASX: IBX), she is also a council member of Deakin University.

Additionally, Ms Angus holds a Master of Biotechnology, Bachelor of Science (Hons), and a Graduate Diploma of Intellectual Property (IP) Law. She is a registered patent attorney and a member of Australian Institute of Company Directors (AICD).

Effective 1 December 2023, current Chair Mr Geoff Pocock will step down from this role and continue as a Non-Executive Director. Following the appointment of Ms Angus, the Argenica Board will have an independent Non-Executive Chair and a majority of independent Non-Executive Directors in line with the ASX Corporate Governance Principles & Recommendations.

Ms Angus said: “I am excited to join the Argenica Board as it embarks on its first Phase 2 trial of ARG-007 in ischaemic stroke. With the transition of Argenica to a clinical stage neurology company I look forward to bringing my industry and commercialisation experience to the Company”.

Mr Geoff Pocock, Non-Executive Chair, said: “We are delighted to welcome Di to the Argenica Board. We believe that securing a Chair with Di’s extensive breadth of experience in the listed biopharmaceuticals industries and capital markets is a great reflection on the exciting future for Argenica. Di’s ability to drive strong commercial and strategic partnerships and leadership credentials will be an excellent addition to our Board as we embark on the next growth phase of our Company. We look forward to working with Di throughout this exciting next stage of the Company”.

### Key Terms of Engagement as a Non-Executive Director

Term: Commencing 1 December 2023

Compensation: A director's fee of \$95,000 per annum, plus superannuation calculated as per the legislative minimum.

Working hours: As much time as is necessary to perform the role as non-executive director.

*This announcement has been approved for release by the Board of Argenica.*

For more information please contact: [info@argenica.com.au](mailto:info@argenica.com.au)

### **ABOUT ARGENICA**

Argenica (ASX: AGN) is developing novel therapeutics to reduce brain tissue death after stroke and other types of brain injury and neurodegenerative diseases to improve patient outcomes. Our lead neuroprotective peptide candidate, ARG-007, has been successfully demonstrated to improve outcomes in pre-clinical stroke models, traumatic brain injury (TBI) and hypoxic ischaemic encephalopathy (HIE). The Company has recently completed a Phase 1 clinical trial in healthy human volunteers to assess the safety and tolerability of a single dose of ARG-007. Argenica is now progressing towards a Phase 2 clinical trial in ischaemic stroke patients, as well as continuing to generate preclinical data in other neurological conditions, including in TBI, HIE and Alzheimer's Disease.